GlassScriptPhysician profile
Christopher D Naquin
NPI 1760489579
$18,798.42
in general payments reported to CMS, 2019-2025
41 companies · $2,239 in 2025
The $2,239 reported for 2025 was more than what 96% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,840 · 2020: $2,606 · 2021: $2,946 · 2022: $2,790 · 2023: $3,025 · 2024: $2,353 · 2025: $2,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,532 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,531.70 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,682.16 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $2,484.30 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $2,240.28 | 2019-2025 | |
| Novo Nordisk INC | $2,185.36 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,337.53 | 2019-2025 | Jardiance, Spiriva Respimat, Ofev |
| Abbvie INC. | $1,317.21 | 2021-2025 | |
| Lilly USA, LLC | $1,232.30 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $787.54 | 2021-2025 | |
| Amgen INC. | $439.00 | 2019-2024 | Otezla, Repatha, Krystexxa |
| Merck Sharp & Dohme LLC | $403.73 | 2019-2025 | Belsomra, Gardasil 9, Capvaxive |
| Astellas Pharma US INC | $380.04 | 2019-2025 | Veozah, Myrbetriq |
| Teva Pharmaceuticals USA, INC. | $348.03 | 2019-2023 | Austedo Xr |
| Sanofi-Aventis U.S. LLC | $304.68 | 2019-2023 | |
| Biohaven Pharmaceutical Holding Company LTD. | $304.49 | 2022 | |
| Exact Sciences Corporation | $281.27 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Naquin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.